Evaluation of Zoster Immune Plasma: Treatment of Cutaneous Disseminated Zoster in Immunocompromised Patients

Karl E. Groth; Jeffrey McCullough; Stephen C. Marker; Richard J. Howard; Richard L. Simmons; John S. Najarian; Henry H. Balfour

doi:10.1001/jama.1978.03280450049024

Evaluation of Zoster Immune Plasma: Treatment of Cutaneous Disseminated Zoster in Immunocompromised Patients

Karl E. Groth, Jeffrey McCullough, Stephen C. Marker, Richard J. Howard, Richard L. Simmons, John S. Najarian, Henry H. Balfour

Research output: Contribution to journal › Article › peer-review

Abstract

Zoster immune plasma (ZIP) was evaluated for treatment of cutaneous disseminated zoster in immunocompromised hosts. Twenty patients were studied: 13 were enrolled in a double-blind protocol, five received ZIP under an open protocol, and two were observed without receiving a transfusion. In the double-blind study, eight patients actually received ZIP; five were given plasma lacking varicella-zoster virus antibodies (control plasma). The clinical course of zoster in the group given ZIP was the same as that of patients given control plasma or no transfusions. Because ZIP did not alter the clinical course of zoster and because zoster patients produced high-antibody titers without ZIP, we concluded that ZIP is not useful for treatment of cutaneous disseminated zoster and should be reserved for prevention or modification of varicella in exposed, susceptible immunocompromised patients.

Original language	English (US)
Pages (from-to)	1877-1879
Number of pages	3
Journal	JAMA: The Journal of the American Medical Association
Volume	239
Issue number	18
DOIs	https://doi.org/10.1001/jama.1978.03280450049024
State	Published - May 5 1978

Access

10.1001/jama.1978.03280450049024

OpenUrl availability

Full text

Cite this

@article{9ad95aaa12424322b55e28c85de9a6cb,

title = "Evaluation of Zoster Immune Plasma: Treatment of Cutaneous Disseminated Zoster in Immunocompromised Patients",

abstract = "Zoster immune plasma (ZIP) was evaluated for treatment of cutaneous disseminated zoster in immunocompromised hosts. Twenty patients were studied: 13 were enrolled in a double-blind protocol, five received ZIP under an open protocol, and two were observed without receiving a transfusion. In the double-blind study, eight patients actually received ZIP; five were given plasma lacking varicella-zoster virus antibodies (control plasma). The clinical course of zoster in the group given ZIP was the same as that of patients given control plasma or no transfusions. Because ZIP did not alter the clinical course of zoster and because zoster patients produced high-antibody titers without ZIP, we concluded that ZIP is not useful for treatment of cutaneous disseminated zoster and should be reserved for prevention or modification of varicella in exposed, susceptible immunocompromised patients.",

author = "Groth, {Karl E.} and Jeffrey McCullough and Marker, {Stephen C.} and Howard, {Richard J.} and Simmons, {Richard L.} and Najarian, {John S.} and Balfour, {Henry H.}",

year = "1978",

month = may,

day = "5",

doi = "10.1001/jama.1978.03280450049024",

language = "English (US)",

volume = "239",

pages = "1877--1879",

journal = "JAMA: The Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "18",

}

TY - JOUR

T1 - Evaluation of Zoster Immune Plasma

T2 - Treatment of Cutaneous Disseminated Zoster in Immunocompromised Patients

AU - Groth, Karl E.

AU - McCullough, Jeffrey

AU - Marker, Stephen C.

AU - Howard, Richard J.

AU - Simmons, Richard L.

AU - Najarian, John S.

AU - Balfour, Henry H.

PY - 1978/5/5

Y1 - 1978/5/5

N2 - Zoster immune plasma (ZIP) was evaluated for treatment of cutaneous disseminated zoster in immunocompromised hosts. Twenty patients were studied: 13 were enrolled in a double-blind protocol, five received ZIP under an open protocol, and two were observed without receiving a transfusion. In the double-blind study, eight patients actually received ZIP; five were given plasma lacking varicella-zoster virus antibodies (control plasma). The clinical course of zoster in the group given ZIP was the same as that of patients given control plasma or no transfusions. Because ZIP did not alter the clinical course of zoster and because zoster patients produced high-antibody titers without ZIP, we concluded that ZIP is not useful for treatment of cutaneous disseminated zoster and should be reserved for prevention or modification of varicella in exposed, susceptible immunocompromised patients.

AB - Zoster immune plasma (ZIP) was evaluated for treatment of cutaneous disseminated zoster in immunocompromised hosts. Twenty patients were studied: 13 were enrolled in a double-blind protocol, five received ZIP under an open protocol, and two were observed without receiving a transfusion. In the double-blind study, eight patients actually received ZIP; five were given plasma lacking varicella-zoster virus antibodies (control plasma). The clinical course of zoster in the group given ZIP was the same as that of patients given control plasma or no transfusions. Because ZIP did not alter the clinical course of zoster and because zoster patients produced high-antibody titers without ZIP, we concluded that ZIP is not useful for treatment of cutaneous disseminated zoster and should be reserved for prevention or modification of varicella in exposed, susceptible immunocompromised patients.

UR - http://www.scopus.com/inward/record.url?scp=84943985149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943985149&partnerID=8YFLogxK

U2 - 10.1001/jama.1978.03280450049024

DO - 10.1001/jama.1978.03280450049024

M3 - Article

SN - 0098-7484

VL - 239

SP - 1877

EP - 1879

JO - JAMA: The Journal of the American Medical Association

JF - JAMA: The Journal of the American Medical Association

IS - 18

ER -

Evaluation of Zoster Immune Plasma: Treatment of Cutaneous Disseminated Zoster in Immunocompromised Patients

Abstract

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this